Literature DB >> 16513879

BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia.

Takanori Hashimoto1, David A Lewis.   

Abstract

OBJECTIVE: In the prefrontal cortex of subjects with schizophrenia, decreased signaling mediated by brain-derived neurotrophic factor (BDNF) and its receptor tyrosine kinase (TrkB) appears to contribute to the reduced expression of mRNA encoding the 67-kilodalton isoform of glutamate decarboxylase (GAD(67)), an enzyme for GABA synthesis. The authors examined in subjects with schizophrenia the effect in the human BDNF gene of a single nucleotide polymorphism (Val66Met), which reduces the trafficking and secretion of BDNF protein, on the expression of GAD(67) mRNA.
METHOD: BDNF Val66Met genotyping was performed in 27 matched pairs of schizophrenia and comparison subjects. The impact of this polymorphism on prefrontal cortex GAD(67) mRNA expression in schizophrenia subjects was assessed by comparing within-pair differences in GAD(67) mRNA expression between schizophrenia subjects with versus without the Met66 allele after the level of BDNF mRNA expression was controlled.
RESULTS: In contrast to expectations, the within-pair reduction in GAD(67) mRNA expression was not greater in schizophrenia subjects who were hetero- or homozygous for the Met66 allele. These subjects did tend to exhibit less marked within-pair reductions in both GAD(67) and BDNF mRNA expression compared with schizophrenia subjects homozygous for the Val allele.
CONCLUSIONS: The presence of the BDNF Met66 allele does not contribute to the decreased level of GAD(67) mRNA expression in the prefrontal cortex of subjects with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513879     DOI: 10.1176/appi.ajp.163.3.534

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

1.  Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.

Authors:  Francesco Matrisciano; Patricia Tueting; Stefania Maccari; Ferdinando Nicoletti; Alessandro Guidotti
Journal:  Neuropsychopharmacology       Date:  2011-11-16       Impact factor: 7.853

2.  Variance decomposition of MRI-based covariance maps using genetically informative samples and structural equation modeling.

Authors:  J Eric Schmitt; Rhoshel K Lenroot; Sarah E Ordaz; Gregory L Wallace; Jason P Lerch; Alan C Evans; Elizabeth C Prom; Kenneth S Kendler; Michael C Neale; Jay N Giedd
Journal:  Neuroimage       Date:  2008-07-11       Impact factor: 6.556

3.  GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression.

Authors:  Grazyna Rajkowska; Gillian O'Dwyer; Zsofia Teleki; Craig A Stockmeier; Jose Javier Miguel-Hidalgo
Journal:  Neuropsychopharmacology       Date:  2006-10-25       Impact factor: 7.853

4.  Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor.

Authors:  Claudio D'Addario; Maria Carlotta Palazzo; Beatrice Benatti; Benedetta Grancini; Mariangela Pucci; Andrea Di Francesco; Giulia Camuri; Daniela Galimberti; Chiara Fenoglio; Elio Scarpini; A Carlo Altamura; Mauro Maccarrone; Bernardo Dell'Osso
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-08-19       Impact factor: 5.067

5.  Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders.

Authors:  Mia Thompson Ray; Cynthia Shannon Weickert; Eugene Wyatt; Maree J Webster
Journal:  J Psychiatry Neurosci       Date:  2011-05       Impact factor: 6.186

6.  Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Risk of Schizophrenia: A Meta-analysis of Case-Control Studies.

Authors:  Majid Kheirollahi; Elahe Kazemi; Saeideh Ashouri
Journal:  Cell Mol Neurobiol       Date:  2015-07-02       Impact factor: 5.046

7.  Corticosterone antagonist or TrkB agonist attenuates schizophrenia-like behavior in a mouse model combining Bdnf-e6 deficiency and developmental stress.

Authors:  Yanhui Chen; Shangjin Li; Tianyi Zhang; Feng Yang; Bai Lu
Journal:  iScience       Date:  2022-06-16

8.  Loss of TrkB Signaling in Parvalbumin-Expressing Basket Cells Results in Network Activity Disruption and Abnormal Behavior.

Authors:  Dionysios Xenos; Marija Kamceva; Simone Tomasi; Jessica A Cardin; Michael L Schwartz; Flora M Vaccarino
Journal:  Cereb Cortex       Date:  2018-10-01       Impact factor: 5.357

9.  BDNF-Val66Met-polymorphism impact on cortical plasticity in schizophrenia patients: a proof-of-concept study.

Authors:  Wolfgang Strube; Michael A Nitsche; Thomas Wobrock; Tilmann Bunse; Bettina Rein; Maximiliane Herrmann; Andrea Schmitt; Vanessa Nieratschker; Stephanie H Witt; Marcella Rietschel; Peter Falkai; Alkomiet Hasan
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.